Every Form 4 that Caris Life Sciences, Inc. (CAI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CAI filings page.
Caris Life Sciences, Inc. (CAI) reported that President David Baxley Spetzler exercised stock options for a total of 1,250,000 shares of common stock at an exercise price of $2.44 per share on September 3–4, 2026. In connection with these exercises, he sold 597,212 shares in broker-assisted sell-to-cover transactions at weighted average prices around $24.76–$25.32 to cover the aggregate exercise price and tax withholding obligations, and retained all remaining shares acquired upon exercise. The options were fully vested and were exercised before their September 12, 2026 expiration.
Caris Life Sciences director Peter M. Castleman reported an acquisition of 13,192 shares of Common Stock on 2026-08-14, as an award of restricted stock units that vest in accordance with the applicable grant agreement, bringing his directly held shares to 29,321.
He also reports indirect ownership of 108,009 shares held by a family trust and 10,546,384 shares held by CLS-PF-SPE, LLC, where he has voting and investment power through a manager role and disclaims beneficial ownership except to the extent of his pecuniary interest.
PHILLIPS T DANNY reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences, Inc. director Phillips T. Danny received an equity award reported as 13,192 shares of Common Stock, reflected as a grant or award of restricted stock units. The award was at a stated price of $0.00 per share and increased his direct holdings to 133,060 shares. The restricted stock units vest in accordance with the applicable grant agreement.
Minor Lloyd reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences, Inc. reported that director Lloyd Minor received a grant of 13,192 shares of Common Stock in the form of restricted stock units on 2026-08-14 at a stated price of $0.00 per share. These restricted stock units vest in accordance with the applicable grant agreement. Following this award, Minor directly holds 31,813 shares of the company’s Common Stock.
Caris Life Sciences, Inc. reported that director Joseph E. Gilliam received an equity award in the form of 13,192 shares of Common Stock on 2026-08-14, recorded as a grant or award acquisition at no cash price per share. Following this award, his directly held position increased to 29,321 shares. A footnote explains that the award consists of restricted stock units that vest in accordance with the applicable grant agreement.
Caris Life Sciences, Inc. reported that director David Paul Fredrickson received an equity compensation award. He acquired 13,192 shares of Common Stock on August 14, 2026, at a stated price of $0.00 per share, representing an award of restricted stock units that vest under the applicable grant agreement. Following this award, his directly held Common Stock position increased to 31,813 shares.
Vacirca Jeff L reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences director Jeff L. Vacirca received a grant of 13,192 shares of Common Stock on 2026-08-14, reported as an award of restricted stock units that vest under the applicable grant agreement. The award was recorded at $0.00 per share, and his direct holdings increased to 62,863 shares following the grant.
JOHANSEN LAURA I reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences, Inc. reported that director Laura I. Johansen received a grant of 13,192 shares of Common Stock in the form of restricted stock units on 2026-08-14. The award was recorded at $0.00 per share and increased her directly held position to 343,897 shares. According to the accompanying note, these restricted stock units vest in accordance with the applicable grant agreement.
HALBERT JON reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences, Inc. director Jon Halbert reported a grant of 13,192 restricted stock units of common stock on 2026-08-14 at $0.00 per share, vesting under an applicable grant agreement. Following this award, he holds 131,813 shares directly and indirect holdings of 652,062 shares through a family trust and 706,531 shares through LAH Investments, Ltd., where beneficial ownership is disclaimed except for his pecuniary interest.
Caris Life Sciences director Jon Halbert reported an open-market purchase of 68,000 shares of Common Stock on May 15, 2026, at a weighted average price of $14.56 per share, through LAH Investments, Ltd.. These shares were bought in multiple trades between $14.49 and $14.60 per share. Following this transaction, LAH Investments, Ltd. held 704,598 shares indirectly, a family trust held 637,887 shares indirectly, and Halbert held 118,621 shares directly. Some indirect holdings include shares received in pro rata distributions exempt under Rule 16a-9, and Halbert disclaims beneficial ownership except to the extent of his pecuniary interest.
POSTE GEORGE reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences director George Poste reported routine equity compensation and a prior ownership reclassification. He received 1,600 shares of common stock as a grant in lieu of cash 2026 board retainer fees, based on a ten-day average price of $15.62 per share. After this award, he holds 17,729 shares directly. A previous transfer of 204,108 shares from direct ownership into a family trust contributed to an indirect total of 511,702 shares, and did not change his overall beneficial ownership.
Knowles Jonathan Kenneth Charles reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences director Jonathan Kenneth Charles Knowles received 1,600 shares of Common Stock on May 29, 2026 as a stock grant. The shares were issued in lieu of cash compensation for his 2026 board retainer fees, based on a ten-day volume weighted average price calculation. Following this award, he directly owns 308,979 shares of Caris Life Sciences common stock.
Caris Life Sciences executive John Russel Denton reported routine equity compensation activity. On May 15, 2026, 6,047 shares of common stock were withheld at $15.25 per share to cover taxes on the vesting and settlement of RSUs, a non‑market tax-withholding disposition coded "F".
Following this event, Denton directly held 181,515 shares of common stock and indirectly held 9,184 shares through a trust. The filing shows no open-market purchases or sales, indicating a compensation-related adjustment rather than a discretionary trade.
Caris Life Sciences executive Luke Thomas Power used company stock to cover taxes on vested RSUs. On this Form 4, 9,771 shares of Common Stock were withheld at $15.25 per share to pay withholding taxes. After this tax-withholding disposition, he directly holds 153,771 shares.
Caris Life Sciences, Inc. president David Baxley Spetzler reported a routine tax-withholding disposition related to vested RSUs. On the transaction date, 13,856 shares of common stock were withheld at $15.25 per share to cover taxes, leaving him with 530,083 shares owned directly after the transaction.
Caris Life Sciences director Brian J. Brille reported routine equity compensation-related activity involving company common stock. On May 15, 2026, 13,987 shares of common stock were withheld at $15.25 per share to cover taxes on the vesting and settlement of RSUs, which is a tax-withholding disposition rather than an open-market sale.
After this tax withholding, Brille directly held 230,303 shares of common stock. In addition, a family trust held 500,000 shares of common stock, reflecting indirect ownership after previously separate family trusts were consolidated into a single trust. Brille disclaims beneficial ownership of these trust-held shares except to the extent of his pecuniary interest.
Caris Life Sciences director and major holder David D. Halbert reported a routine share disposition tied to equity compensation. On the vesting and settlement of restricted stock units (RSUs), 40,712 shares of Common Stock were withheld at $15.25 per share to cover tax obligations, which is recorded as a tax-withholding disposition rather than an open-market sale.
After this event, Mr. Halbert directly holds 2,574,533 shares of Common Stock. In addition, entities associated with him collectively hold 121,025,002 shares indirectly, including interests in Caris Halbert, L.P., ADAPT I Ltd., Carisome I, L.P., Caris Investment II Ltd., Caris Investment III Ltd., and Halbert Family Capital, LLC, with Mr. Halbert disclaiming beneficial ownership except to the extent of his pecuniary interest.
Caris Life Sciences director Jeff L. Vacirca purchased 31,050 shares of Common Stock in an open-market transaction. The weighted average purchase price was $16.149 per share, with individual trade prices ranging from $16.13 to $16.15. Following this purchase, he directly owns 49,671 shares.
Power Luke Thomas reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences, Inc. executive Luke Thomas Power received an equity grant in the form of restricted stock units. The award covers 63,971 shares of Common Stock, granted at no cash cost to him as compensation. According to the footnote, these restricted stock units will vest in line with the terms of the applicable grant agreement. Following this grant, he directly holds 163,542 shares of Common Stock.
Denton John Russel reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences, Inc. officer John Russel Denton received a grant of 63,971 shares of Common Stock on March 6, 2026, reported as restricted stock units that will vest under the applicable grant agreement. Following this grant, he holds 187,562 shares directly and 9,184 shares indirectly through a trust.
Spetzler David Baxley reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences, Inc. President David Baxley Spetzler received an award of 83,162 shares of Common Stock in the form of restricted stock units. The award was granted at no cash cost per share and will vest in accordance with the applicable grant agreement. Following this compensation-related grant, he holds 543,939 shares of Common Stock directly.
Brille Brian J reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences director and officer Brian J. Brille received a grant of 83,162 shares of Common Stock in the form of restricted stock units on March 6, 2026, at no cash cost, as compensation that will vest under the applicable grant agreement.
Following this grant, he directly holds 244,290 Common shares. In addition, a family trust holds 500,000 Common shares, with Brille reporting the position indirectly and disclaiming beneficial ownership except for his pecuniary interest.
Caris Life Sciences director and officer David D. Halbert reported an acquisition of 320,112 shares of Common Stock on March 6, 2026 as a restricted stock unit award that vests under its grant agreement. These shares were received at a stated price of $0.00 per share, bringing his directly held Common Stock to 2,615,245 shares after the transaction.
The filing also shows 121,025,002 shares of Common Stock held indirectly through several affiliated entities, including Caris Halbert, L.P., ADAPT I Ltd., Carisome I, L.P., Caris Investment II Ltd., Caris Investment III Ltd., and Halbert Family Capital, LLC. Halbert has voting and investment power over these entity holdings but disclaims beneficial ownership beyond his pecuniary interest.
Minor Lloyd reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences director Lloyd Minor reported receiving 2,492 shares of common stock on February 26, 2026. These shares were issued as equity in lieu of cash compensation for his 2025 board retainer fees, based on a ten-day average trading price. Following this award, his direct holdings increased to 18,621 shares of common stock.
Caris Life Sciences director Jeff L. Vacirca received a stock grant instead of cash board fees. On February 26, 2026, he acquired 2,492 shares of common stock at $20.06 per share as compensation for his 2025 board retainer, bringing his direct holdings to 18,621 shares.
Caris Life Sciences director David Paul Fredrickson acquired 2,492 shares of common stock as compensation. The shares were issued on February 26, 2026 in lieu of cash payment for his 2025 board retainer fees, valued at $20.06 per share.
After this stock award, his directly held stake increased to 18,621 common shares. The number of shares granted was calculated by dividing the cash retainer earned by the 10-day average volume-weighted average price per share through February 25, 2026.
HALBERT JON reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences director Jon Halbert received a grant of 2,492 shares of common stock as part of his 2025 board retainer, issued in stock instead of cash. The number of shares was based on the ten‑day average volume-weighted price through February 25, 2026 at $20.06 per share.
After this award, he directly holds 118,621 shares. An additional 625,000 shares are held indirectly through LAH Investments, Ltd., and 625,000 shares are held indirectly through the Jon and Linda Halbert Management Trust, following an in-kind distribution from Ke'Ohana Ventures, LLC. He disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.
PHILLIPS T DANNY reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences director T. Danny Phillips received a stock grant instead of cash for 2025 board retainer fees. He was awarded 3,739 shares of common stock at a reference price of $20.06 per share, bringing his direct holdings to 119,868 shares.
CASTLEMAN PETER M reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences director Peter M. Castleman received a grant of 5,509 shares of common stock on February 26, 2026, as compensation for his 2025 board retainer fees, instead of cash. The shares were valued at $20.06 each, based on a ten-day volume-weighted average price through February 25, 2026.
After this award, he directly holds 24,138 common shares. He also has indirect holdings reported as 100,000 shares through a family trust and 10,270,906 shares held by CLS-PF-SPE, LLC, an entity whose manager controls voting and investment power, while he disclaims beneficial ownership beyond his economic interest.
Caris Life Sciences director Peter M. Castleman reported an option exercise and updated share holdings. On January 9, 2026, he exercised a stock option to acquire 2,500 shares of common stock at an exercise price of $18.6 per share, increasing his directly held common stock to 18,629 shares. The stock option position reported in this filing is now shown as 0 derivative securities remaining.
Castleman also reports indirect ownership of 100,000 common shares through a family trust and 10,270,906 common shares held by CLS-PF-SPE, LLC, where he has voting and investment power through CLS-PF-SPE Manager, LLC, while disclaiming beneficial ownership except to the extent of his pecuniary interest. The option was already fully vested and had been previously reported on his Form 3.
Caris Life Sciences, Inc. reported insider transactions by a Senior Vice President, Chief Financial Officer, and Chief Accounting Officer on 12/11/2025. The officer exercised stock options to acquire 24,750 and 37,500 shares of common stock at an exercise price of $2.44 per share.
On the same date, the officer sold 60,850 shares at a weighted average price of $26.5644 and 1,400 shares at a weighted average price of $27.1554, in multiple transactions within stated price ranges. These option exercises and sales were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. Following the transactions, the officer directly owns 99,571 shares of Caris Life Sciences common stock, and the reported stock options have been fully exercised.
Caris Life Sciences, Inc. reported that one of its directors and executive officers, who serves as Vice Chairman and Executive Vice President, made two stock gifts of the company’s common stock. On 12/10/2025 and 12/11/2025, the insider transferred 650 shares on each date as gifts at a reported price of $0 per share, reflecting that these were non-cash transfers.
After these transactions, the insider beneficially owns 161,128 shares of Caris common stock directly. In addition, 500,000 shares are reported as indirectly owned through trusts, with the insider stating that beneficial ownership of those shares is disclaimed except to the extent of any pecuniary interest. No derivative securities were reported.
Caris Life Sciences (CAI) reported an insider purchase on a Form 4. J. Russel Denton, Senior Vice President, General Counsel, and Secretary, bought 4,184 shares of common stock on 11/07/2025 at a weighted average price of $24.09, with trades executed between $23.99 and $24.15.
After this transaction, he beneficially owns 9,184 shares indirectly by trust and 123,591 shares directly. The price range note indicates multiple trade executions aggregated into the reported average.
Caris Life Sciences (CAI) filed a Form 4 reporting an open‑market purchase by its President. On 11/07/2025, the officer bought 400 shares of common stock at $23.85 (transaction code P). Following the trade, the reporting person beneficially owns 460,777 shares, held directly.